17 - american college of rheumatology · welcome address by acr president 3 welcome address by esr...

The 4th Annual Conference of theEmirates Society For Rheumatologyin partnership with the American College of Rheumatology

President of ACR:Dr. David I. DaikhPresident of ESR:Dr. Waleed AlShehhi

19 - 22 September 2018 | Dubai Festival City

17

For the First Time in the Region ESR is Joining Hands with the ACR


The 4th Annual Conference of the Emirates Society For Rheumatologyin partnership with the American College of Rheumatology

2

TABLE OF CONTENTS

3Welcome Address by ACR President

4Welcome Address by ESR President

5Scientific Committee

6Faculty List

7About Dubai

8ESR-ACR Speakers Profile

15Program: Wednesday, September 19th

16Program: Thursday, September 20th

17Program: Friday, September 21st

18RPS Speakers Profile

22Acknowledgements

20Program: Saturday, September 22nd

23Companies Profile



3

Greetings attendees!

The American College of Rheumatology (ACR) is pleased to collaborate with the Emirates Society for Rheumatology (ESR) by co-hosting the 4th Annual ESR Conference. This conference marks a first-time partnership and brings together thought leaders from both organizations to provide you with more than 30 presentations featuring emerging research and noteworthy topics in the field of rheumatology.

Our partnership is designed to expand and share rheumatology knowledge on a global level to benefit all involved and to ultimately improve care of our patients. In addition to participating in live sessions with leading clinicians and researchers, attendees will receive a year-long complimentary subscription to ACR Beyond, a new online streaming platform from the American College of Rheumatology. ACR Beyond offers access to a combination of top-rated recorded educational sessions from past meetings as well as select live event streams from the ACR’s upcoming annual meeting in Chicago this October.

We are aligned with the ESR’s mission of improving the standard and quality of rheumatologic care. Together, in support of that mission, we have designed a compelling program which features the latest developments in clinical care and research. We hope that the success of this event will allow us to continue to share resources that advance the study and practice of rheumatology internationally.

Regardless of where you practice, ACR can help you save money and time, connect you with colleagues around the world, and enhance your rheumatology knowledge and skills. Please be sure to visit the ACR Booth in the exhibit hall to

learn more about the ACR or ask our staff any questions.

Sincerely and with best regards,

David I. Daikh, MD, PhD President, American College of Rheumatology

Professor of Medicine Kenneth H. Fye Chair in Rheumatology Director, Rheumatology Fellowship ProgramUniversity of California, San Francisco

Chief, Rheumatology Section San Francisco VA Medical Center



4

Dear Colleagues and Friends,

On behalf of the Emirates Society for Rheumatology (ESR), and in partnership with the

American College for Rheumatology (ACR) it is our pleasure to invite you to the 4th Emirates

Society for Rheumatology Annual Conference which will be held between the 19th till the

21st of September 2018 at the Dubai Festival City.

This congress is aimed at creating a main platform for Rheumatology meetings in the

region, bridging rheumatologists in various specialties and aims at covering Rheumatoid Arthritis, SpondyloArthritis,

Vasculitis, Connective Tissue Diseases, Rare Diseases, Osteoporosis, Systemic lupus erythematous and much more.

We are more than confident that this scientific gathering will serve as an excellent networking platform with our fellow

colleagues to exchange professional experiences and insights with one another, as well as to explore possible forms of

international collaborations in research and education.

World renowned speakers from ACR and ESR will come together in this highly anticipated event and from this specialized

area to contribute in the literature of Rheumatology and present state-of-the art advances and updates in the field.

Attendees are expected from all over GCC and neighboring countries as well as from USA and Europe enriching the

congress with a multitude of diversities and backgrounds.

In closing, we aim at transforming the way we operate as Rheumatologists in the hope of continuously improving our

ability to perform and meet our daily challenges in our field. We not only want to offer you a unique opportunity but

would like to thank you for helping us shape the future in the field of Rheumatology.

Dr. Waleed AlShehhiConsultant Rheumatologist President of the Emirates Society for Rheumatology



5

SCIENTIFIC COMMITTEE

Emirates Society For Rheumatology Planning & Executive Committee

Waleed AlShehhi President of the Emirates Society For Rheumatology

Atheer Alansari Acting Vice President

Imad Jassim President of the Scientific Committee

Bhavna Khan

Humeira Badsha

Ghita Harifi

Ahmed Abogamal

Gamal Ibrahim

American College of Rheumatology Planning Committee

David I. Daikh, MD, PhD President of the American College of Rheumatology

Paula Marchetta, MD, MBA ACR President-Elect

Sharad Lakhanpal, MBBS, MD Course Director, 2018 ESR-ACR Annual Conference ACR, Immediate Past President

American College of Rheumatology Executive Committee

David I. Daikh, MD, PhD President of the American College of Rheumatology

Paula Marchetta, MD, MBA ACR President-Elect

Charles M. King, II, MD ACR Treasurer

Ellen Gravallese, MD ACR Secretary

Abby G. Abelson, MD Foundation President

Sandra J. Mintz, MSN, RN ARHP President



6

FACULTY LIST

Atheer Al-Ansari

Basil Fathallah

Carol Langford

Christopher Ritchlin

David Daikh

Dinesh Khanna

Hiba Azar

Imad Jassim

James R. O’Dell

Kenneth Saag

Michelle Petri

Mohammed Omair

Mohsin Malek

Mustafa El-Izzi

Omar Hadid

Peter Nigrovic

Rajaie Namas

Sharad Lakhanpal

Waleed AlShehhi



7

Dubai is located on the Eastern coast of the Arabian Peninsula, in the south west corner of the Arabian Gulf. It is

extremely well known for its warm hospitality and rich cultural heritage, and the Emirati people are welcoming and

generous in their approach to visitors. With year-round sunshine, intriguing deserts, beautiful beaches, luxurious hotels

and shopping malls, fascinating heritage attractions and a thriving business community, Dubai receives millions of

leisure and business visitors each year from around the world.

Dubai Economy: The past few decades have witnessed incredible growth throughout all sectors of the Dubai economy.

The emirate’s government is constantly working to improve its commercial transparency and introduce dynamic

regulations that aid the formation of small and medium enterprises. Dubai’s economy is no longer reliant on oil, but is

more diversified, relying heavily on trade, services and finance sectors. With its central geographic location between

Asian and European markets, Dubai has worked hard to establish itself as an integral part of the global trade mechanism.

Its central location has also allowed Dubai to become a popular and accessible tourist destination.

ABOUT DUBAI



8

Atheer Al AnsariDr. Atheer Al-Ansari is a Consultant rheumatologist trained and worked in UK for 18 years and just moved to Abu Dhabi. Originally he graduated from Baghdad University and trained in UK, he is holding the CCST degree in rheumatology and FRCP Glasgow / London and MRCP Ireland. He was a consultant Rheumatologist at Robert Jones and Agnes Hunt tertiary center and principal investigator at their research unit. He moved to Abu Dhabi 3 years ago as consultant rheumatologist at Mediclinic Middle EAST International Hospitals. Moreover, he is Board member the head of scientific committee at Emirates Society for Rheumatology (ESR), member of Emirates Society for Osteoporosis (EOS) and co-Chair Scientific Committee for the 19th Asian and Pacific League Against Rheumatism (APLAR) in Dubai 2017. Dr. Al-Ansari has numerous publications and presentations promoting the best practice of Rheumatology

Waleed AlShehhiPresident of the Emirates Society For Rheumatology• Dr. Waleed AlShehhi is a Consultant Rheumatologist at Dr. Sulaiman Al Habib Hospital, Dubai Health Care City• Chairman for the Asia Pacific league against Rheumatism 2017 in Dubai• Dr. AlShehhi obtained his medical degree and Rheumatology specialty from the Royal College of Surgeons and Physicians, respectively, from Ireland.• Dr. AlShehhi is a certified EULAR MSK-US Teacher, examiner for the Royal college of physicians Ireland, Fellow for the RCPI, fellow of the ACR

Hiba Azar Dr Hiba AZAR graduated from the Saint Joseph University, Faculty of medicine, Beirut, in 2003 and obtained her diploma in Nephrology and Arterial Hypertension in 2008. She has a Master’s degree of Immunology from Descartes, Paris 5 University. After an experience of a few years in Paris, she returned back home and is actually practicing in the Nephrology Department at Hotel Dieu de France University Hospital, Beirut. She is also Clinical Instructor in Saint Joseph University. Dr AZAR has a special interest in kidney transplantation and in glomerular diseases and works in collaboration with her rheumatology colleagues treating patients with systemic diseases.

ESR-ACR SPEAKERS PROFILE



9

David DaikhPresident of the American College of Rheumatology. Dr. David Daikh is the Rheumatology Division Chief at the SFVA Medical Center, and director of the rheumatology fellowship program at UCSF. Dr. Daikh’s research focuses on immune mechanisms of rheumatic disease, and he directs a core laboratory that serves a number of investigators at UCSF.

Mustafa El-IzziSenior Consultant Rheumatologist at Mediclinic Welcare Hospital, Mediclinic City Hospital and Mediclinic Dubai Mall, Dubai, United Arab Emirates since October 2011Member of the Royal College of Physicians (MRCP-UK) since 1982 Fellow of the Royal College of Physicians of Edinburgh FRCP (Edin) since 2000 Current Vice President of the Emirates Osteoporosis Society (EOS)

Basil FathallahDr. Basil Fathalla, is a pediatric rheumatology consultant at Al Jalila Children’s Specialty Hospital in Dubai since January 2016. Dr. Fathalla completed his medical school at the School of Medicine – Damascus University, Syria during 1989 – 1996 and Pediatric Residency training at Henry Ford Hospital in Detroit, USA during1997 – 2000. Dr. Fathalla then completed pediatric rheumatology training at the Floating Hospital for Children / The New England Medical Center / Tufts University in Boston USA during 2000 - 2003. Dr. Fathalla is American Board Certified in Pediatrics and Pediatric Rheumatology and gained his experience through academic positions in various tertiary care hospitals including St. Christopher’s Hospital for Children in Philadelphia, Children’s Hospital of Michigan in Detroit, and Hamad General Hospital in Qatar.

Omar HadidOmar Hadid is a consultant ophthalmologygist at Tawam Hospital. He has dual qualifications after undertaking training both in general medicine and ophthalmology. He has a special interest in inflammatory eye disease and has had special training in the world-renowned medical eye unit at St Thomas' Hospital in London. He also has specialised training in Oculoplastics and Orbital diseases. He has worked as a consultant in the NHS in the UK for over 6 years. He also has an interest in training and reaesch and is an honorary Clinical Lecturer in the University of Sheffield




10

Imad Jassim• Graduated Baghdad University with MBChB in Medicine and Surgery• Certified Diploma in Internal Medicine University of London, Imperial college 1995 with distinction

• Completed medical training in UK achieving MRCP London 1999• Completed MSc in clinical rheumatology from Manchester university 2006• Achieved CCT in rheumatology from Royal College of London 2007• Consultant Rheumatologist in England from 2005 -now• Last job was in East Kent University Hospital NHS Trust from 2011-2014• Moved to UAE 2014 Currently Consultant Rheumatologist and Head of department• Head of the Scientific committee of ESR

• Member of British society of rheumatology

Dinesh KhannaMD, MScUniversity of Michigan, Ann Arbor, MI Dinesh Khanna, MD, MSc, is an Professor of Medicine and Director, University of Michigan Scleroderma Program. Dr. Khanna has published over 300 peer-reviewed articles and book chapters. His current research focus on developing, validating, and refining outcome measures in rheumatic diseases and designing novel trials. He was awarded the 2015 Henry Kunkel Young Investigator Award from the American College of Rheumatology.

Sharad LakhanpalImmediate Past President, American College of Rheumatology Rheumatology Associates, Dallas, TX Dr. Sharad Lakhanpal is a practicing rheumatologist in Dallas, TX, USA. He is Clinical Professor of Internal Medicine at UT Southwestern Medical Center in Dallas, TX. He is also an investigator at Metroplex Clinical Research Center in Dallas. He did rheumatology fellowship at Mayo Clinic and received several awards during his training. He has been listed in the Best Doctors in America since 1996. He has over 100 publications. He is a Fellow of the American College of Rheumatology and the American College of Physicians.


Carol LangfordMD, MHSCleveland Clinic, Cleveland, OH Carol A. Langford, MD, MHS is the Director of the Center for Vasculitis Care and Research within the Department of Rheumatic and Immunologic Diseases. She is an Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and became Vice-Chair of Rheumatology for Research in 2007. In 2011, she was named the Harold C Schott endowed Chair in Rheumatic and Immunologic Diseases.



11

Mohsin MalekFRCP UKConsultant DermatologistDr Mohsin Malik is an established and highly skilled physician with over 20 years of experience in dermatology. He completed his specialist dermatology training in Republic of Ireland before moving to UK where he worked as Consultant Dermatologist at Royal London Hospital and Chief of Dermatology at Broomfield Hospital. He was also Honorary Senior Lecturer at Barts and The London. He is now in UAE since 2014 working at Tawam Hospital affiliated with Johns Hopkins as a Senior Dermatologist. Dr Malik is Fellow of Royal College of Physicians UK, and member of Royal Society of Medicine UK, and Emirates Dermatology Society, and has a number of publications and presentations at international meetings

to his credit. Dr Malik deals with both adult and pediatric dermatology with special interest in eczema, cutaneous allergy, acne, psoriasis and skin cancer.

Rajaie NamasMBBCh . Dr Namas is a Staff Physician in the Medical Subspecialties Institute at Cleveland Clinic Abu Dhabi.Prior to joining Cleveland Clinic Abu Dhabi, Dr. Namas served at the University of Michigan as a Clinical Lecturer for two years, and was supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases. He was then promoted to Clinical Assistant Professor at the University of Michigan. Dr. Namas received his medical degree from the University of Tripoli, Libya. He completed his postdoctoral training at the University of Pittsburgh, Pennsylvania, US, followed by his residency in Internal Medicine at Hurly Medical Center/Michigan State University in Flint, Michigan, US. Dr. Namas completed his clinical and research fellowship in Rheumatology at the Wayne State University/Henry Ford Hospital in Detroit, Michigan, US. Dr. Namas is currently active in numerous research projects focused on treatment strategies,

measures of outcome, and translational studies of potential laboratory markers of disease activity.He has multiple publications and awards in the field of Rheumatology, and is a reviewer on multiple peer-reviewed journals. Dr. Namas is a member and fellow of the American College of Rheumatology and American College of Physicians.


Peter Nigrovic MDBrigham and Women's Hospital, Boston, MA Dr. Peter Nigrovic is Associate Professor of Medicine at Harvard Medical School and an adult and pediatric rheumatologist at Boston Children’s Hospital and the Brigham and Women’s Hospital. His laboratory studies basic mechanisms of inflammation, with a focus on autoimmune arthritis. He leads the Center for Adults with Pediatric Rheumatic Illness (CAPRI), a clinical program dedicated to the care of adults with childhood-onset rheumatic illness. He directs translational research for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and is co-editor of Arthritis & Rheumatology.



12


Michelle PetriMD - Johns Hopkins University School of Medicine, BaltimoreMichelle Petri is a Professor of Medicine in the Division of Rheumatology and Director of the Lupus Center at the Johns Hopkins University School of Medicine and Johns Hopkins.Professor Petri’s research focuses on several aspects of systemic lupus erythematosus (SLE), including atherosclerosis, antiphospholipid syndrome (APS), lupus nephritis, and pregnancy. The Hopkins Lupus Cohort, started by Professor Petri in 1987, is a longitudinal study of the incidence and pathogenesis of thrombotic events and coronary artery disease in SLE and serves as a useful resource for other SLE-related research. The Hopkins Lupus Pregnancy Center, of which Professor Petri is a Co-Director, has a database of over 400 pregnant patients, providing information on lupus activity, antiphospholipid tests, and pregnancy outcomes. Professor Petri has authored over 400

papers and chapters on SLE and APS.

James R. O’DellMD - Past President, American College of RheumatologyUniversity of Nebraska Medical Center, Omaha, NEJames R. O’Dell, MD is the Stokes Schackleford Professor of Internal Medicine, Vice-Chairman of Internal Medicine and Chief of Rheumatology at the University of Nebraska Medical Center and the Omaha VA. He also has served as Director of the Internal Medicine Residency Training Program at UNMC for the last 25.Dr. O’Dell founded and has directed the Rheumatoid Arthritis Investigational Network (RAIN) for the last 22 years. Dr. O’Dell is the PI of the large multinational RA research comparative effectiveness study based at the VA. Dr. O’Dell has published extensively, mostly in the area of RA. He is the co-editor of the “Textbook of Rheumatology” and editor of “Kelley’s Textbook of Medicine”.

Mohammed OmairDr. Mohammed Omair is an associate professor and rheumatologist at King Saud University.His area of interest includes systemic sclerosis and rheumatoid arthritis.He is the founding president of the Charitable Association for Rheumatic diseases



13


Christopher Ritchlin MD, MPH - University of Rochester, Rochester, NY

Christopher Ritchlin, MD, MPH is a Professor of Medicine and Division Chief of the Allergy, Immunology & Rheumatology Division at University of Rochester Medical Center in Rochester, New York. Dr. Ritchlin's laboratory is engaged in translational research that is centered on mechanisms of bone resorption in psoriatic arthritis and axial spondylarthritis and on the role of the lymphatic system in joint flares observed in rheumatoid and psoriatic arthritis.

Kenneth SaagMD, MS - University of Alabama Birmingham, Birmingham,AL Kenneth Kenneth Saag, MD, MSc, is the Jane Knight Lowe Professor of Medicine, Division of Clinical Immunology and Rheumatology, at the University of Alabama at Birmingham. He is Vice-Chair for the UAB Department of Medicine and Director of the Center for Outcomes Research (COERE). He’s published over 300 peer-reviewed manuscripts; authored over 100 reviews, editorials, and book chapters. He recently published the second edition of the “Diagnosis and Management of Osteoporosis” Dr. Saag is a past board member of the ACR, and co-developer of the 2008 and 2011 ACR Recommendations on the Treatment of Rheumatoid Arthritis. He is the Past President of the National Osteoporosis Foundation.

David WalkerTBA



14



15

Wednesday 19th September 2018

08:00 - 08:30 Welcome Note by the President of the Emirates Society forRheumatology

Waleed AlShehhi

08:30 - 10:00 Session I Chair: Waleed AlShehhi08:30 - 09:15 Ophthalmology For Rheumatologists Omar Hadid09:15 - 10:00 Nephrology For Rheumatologists Hiba Azar

10:00 - 10:15 Coffee Break

10:15 - 11:45 Session II Chair: Abullatif Al-Arfaj10:15 - 11:00 Dermatology For Rheumatologists Mohsin Malek11:00 - 11:45 Respiratory For Rheumatologists Mohammed Omair

11:45 - 12:30 Symposium Sponsored by Pfizer

12:30 - 13:30 Lunch Break

13:30 - 15:00 Session III: Special Interest - Group Session Chair: Mohamed Omair13:30 - 14:00 Presentation On Rheumatoid Arthritis1 Imad Jassim14:00 - 14:30 Presentation On Osteoporosis Mustafa El-Izzi14:30 - 15:00 Presentation On Connective Tissue Disease Rajaie Namas

15:00 - 15:45 IL-17A Inhibition in Spondyloarthritis: Long Term Implicationsfor Clinical Practice

Symposium Sponsored by Novartis

Dr. Atheer Al AnsariDr. Imad Jassim


16:00 - 17:30 Session IV: Special Interest - Group Session Chair: Imad Jassim16:00 - 16:30 Presentation On Spondyloarthritis/Psoriatic Arthritis Waleed AlShehhi 16:30 - 17:00 Presentation On Juvenile Arthritis Basil Fathallah17:00 - 17:30 Serositis and its Clinical Implications Atheer Al-Ansari



16

Thursday 20th September 2018

08:00 - 08:30 Welcome Note By the American College of Rheumatology David DaikhSharad Lakhanpal

08:30 - 10:00 Session V Co-Chairs: Sharad Lakhanpal - Waleed AlShehhi08:30 - 09:15 Update On Clinical Aspects And Treatment Of ANCA Associated Vasculitis Carol Langford09:15 - 10:00 Non-Radiographic Spondyloarthritis From Diagnosis To

ManagementChristopher Ritchlin


10:15 - 11:45 Session VI Co-Chairs: Sharad Lakhanpal - Bhavna Khan10:15 - 11:00 New Classification Criteria For SLE David Daikh11:00 - 11:45 Evidence-Based Treatment of Lupus Nephritis Michelle Petri

11:45 - 12:30 Symposium Sponsored by Pfizer

12:30 - 13:30 Lunch Break

13:30 - 15:00 Session VII Co-Chairs: Sharad Lakhanpal - Ghita Harifi13:30 - 14:15 Management Of Scleroderma Dinesh Khanna14:15 - 15:00 Update On Clinical Aspects And Treatment Of Large Vessel

VasculitisCarol Langford

15:00 - 15:45 Challenging the Rheumatoid Arthritis Treatment Standards with JAKInhibitors: Can we Change the Paradigm?

Symposium Sponsored by Lilly

David Walker


16:00 - 17:30 Session VIII Co-Chairs: Sharad Lakhanpal - Mustafa Al Izzi16:00 - 16:45 Difficult to Treat Rheumatoid Arthritis James R. O’Dell16:45 - 17:30 Osteoporosis 2018: Bones of Contention Kenneth Saag

17:30 - 18:15 Symposium Sponsored by Lilly



17

Friday 21st September 2018

08:30 - 10:00 Session IX Co-Chairs: Sharad Lakhanpal - Rajaie Namas08:30 - 09:15 Auto Inflammatory Conditions Diagnosis and Management Peter Nigrovic09:15 - 10:00 Scleroderma-Associated ILD and PAH Dinesh Khanna


10:15 - 11:45 Session X Co-Chairs: Sharad Lakhanpal - Humeira Badsha10:15 - 11:00 Evidence-Based Management of Early Rheumatoid Arthritis James R. O’Dell11:00 - 11:45 Gout and Hyperuricemia: Comorbidities and Complexities with Therapies Kenneth Saag

11:45 - 13:00 Prayer Followed By Lunch

13:00 - 13:45 Symposium Sponsored by GSK

13:45 - 15:15 Session XI Co-Chairs: Sharad Lakhanpal - Gamal Ibrahim13:45 - 14:30 Optimal Management of Psoriatic Arthritis Christopher Ritchlin14:30 - 15:15 Systemic JIA and Adult Onset Still’s Disease Peter Nigrovic


15:30 - 17:00 Session XII Co-Chairs: Sharad Lakhanpal - Ahmed Abogamal15:30 - 16:15 Biomarkers for SLE and Connective Tissue Diseases

Now and in the FutureDavid Daikh

16:15 - 17:00 Anti-phospholipid Antibodies, APLS and Management of theHypercoaguable Patient

Michelle Petri

17:45 - 18:15 Closing Ceremony



18

Abdurrahman AlbaityConsultant Internist, Rheumatology Fellow, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia

Faiza AljishiConsultant Internist and Rheumatologist, Chairwoman, Department of Medicine; Section Head, Division of Rheumatology; King Fahd Specialist Hospital, Dammam, Saudi Arabia.

Hani AlMoallimCanadian and American boards in Internal Medicine and Rheumatology, Professor of Medicine, Vice-dean, Medical College, Umm Al-Qura University, Makkah, Saudi Arabia. Consultant Rheumatologist and Educationalist with Medical Education diploma from University of Dundee. Supervisor, Alzaidi Chair of Research in Rheumatic Diseases

RPS SPEAKERS PROFILE

Mohammed AttarConsultant Internist and Rheumatologist, Armed Forces Hospital, Alhada, Saudi Arabia. Subspecialized in systemic lupus erythematosus.

Suzan AttarProfessor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah, Saudi Arabia. Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah, Saudi Arabia.



19

Sami BahlasProfessor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah, Saudi Arabia. Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah.

Mayadah BawayanConsultant Internist and Rheumatologist, East Jeddah Hospital, Jeddah, Saudi Arabia.

Yasir BawazeerAssistant Professor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah, Saudi Arabia. Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah.

RPS SPEAKERS PROFILE

Waleed HafizAssistant Professor of Medicine and Rheumatology, Medical College, Umm Al-Qura University, Makkah, Saudi Arabia. Consultant Rheumatologist, Alnoor Specialist Hospital, Makkah, Saudi Arabia. Scientific Coordinator, Alzaidi Chair of Research in Rheumatic Diseases.



20

SATURDAY 22ND SEPTEMBER 2018

Rheumatology Practice Symposium (RPS)In collaboration with Alzaidi Chair of Research in Rheumatic DiseasesUmm Alqura University Makkah, Saudi Arabia

08:00 - 08:15 Welcoming and Highlights of the Program Hani AlMoallim

08:00 - 09:45 Basics in Rheumatology08:15 - 08:45 Approach to Arthritis Hani AlMoallim08:45 - 09:15 Laboratory Interpretation in Rheumatic Diseases Abdurrahman Albaity09:15 - 09:45 Pharmacotherapy in Rheumatology Waleed Hafiz


10:00 - 12:20 MSK Examination Workshops10:00 - 10:15 General Introduction and Principles of MSK Examination Hani AlMoallim10:15 - 12:20 Workshops Instructors Supervisors10:15 - 10:40 Hands Mawada Bahwairith & Weam Alharbi Sami Bahlas10:40 - 11:05 Shoulders Raha Alturki & Reem Alqarra Yasir Bawazeer11:05 - 11:30 Knee Ayman Esa & Abdullah Hussaini Mohammed Attar11:30 - 11:55 Hips Rayan AlGhamdi & Ibrahim Almane Faiza Aljishi11:55 - 12:20 Back Hadeel Albar, Huda Mehkri & Fida Taha Suzan Attar

12:20 - 13:00 Prayer & Lunch

13:00 - 14:45 Comprehensive Examination of Common Rheumatic Diseases and Presentations13:00 - 13:45 General Introduction and Principles of Comprehensive Exam Waleed Hafiz13:45 - 14:45 Rotating Workshops13:45 - 14:00 Patients with Suspected Mononeuritis Multiplex Yasir Bawazeer14:00 - 14:15 Patients with Early Arthritis (RA and/or SLE) Abdurrahman Albaiti14:15 - 14:30 Patients with Suspected Vasculitis and/or Myopathy Mayadah Bawayan14:30 - 14:45 Patients with Suspected Scleroderma Waleed Hafiz


15:00 - 16:45 Management of Common Rheumatological Diseases: Case-Based Discussions and Reviews15:00 - 15:20 Rheumatoid Arthritis Hani Almoallim15:20 - 15:40 Pregnancy and Rheumatic Disease Faiza Aljishi15:40 - 16:00 Crystal Induced Arthritis Sami Bahlas16:00 - 16:20 Spondyloarthritis Suzan Attar16:20 - 16:40 Systemic Lupus Erythematosus Mohammed Attar

16:40 - 16:45 Closing Remarks and Certificates



21

● Superior reductions in SLE disease activity.2,‡

● A 39% relative risk reduction of severe flare.2,§

● A reduction in corticosteroid dose in patients on ≥7.5 mg/day at baseline.2,¶

● An improvement in fatigue scores as early as Week 8.2,¥

● Similar adverse event profile to standard therapy alone.1

1. Benlyta Local Prescribing Information. 2. van Vollenhoven RF et al. Ann Rheum Dis. 2012; 71: 1343-1349. *Defi ned by low complement and positive anti-dsDNA at baseline. †BLISS-52 and BLISS-76 pooled data. ‡51.5% SRI response rate vs. 31.7% with standard therapy + placebo (p<0.001). §HR (95% CI) 0.61 (0.44, 0.85); p=0.004 vs. placebo + standard therapy. ¶≤7.5 mg/day reduction in 24.6% vs. 15.0% with standard therapy + placebo (p=0.035). ¥FACIT-Fatigue score improvement from baseline at week 52 (least-squares mean) 4.07 vs. 1.80 with placebo + standard therapy (p=0.004).

Abbreviated Prescribing Information for use in UAE, Kuwait & Oman based on BENLYSTA prescribing Information (GDS11IPI09). It is prepared to meet the requirements of the GSK International Pharmaceutical Promotional and Marketing Policy. BENLYSTA is a recombinant, fully human, IgG1λ monoclonal antibody. It’s a sterile lyophilised powder in a single use 120 and 400 mg vials. Indications: BENLYSTA is indicated for reducing disease activity in adult patients with active autoantibody positive systemic lupus erythematosus (SLE) who are receiving standard therapy. Dosage and Administration: The recommended dosage regimen for adult patients (18 years old and above) is 10 mg/kg on Days 0, 14 and 28, and at 4-week intervals thereafter. BENLYSTA is administered intravenously by infusion over a 1-hour period, and must be reconstituted and diluted prior to administration. It should be administered by a healthcare professional prepared to treat hypersensitivity reactions including anaphylaxis. Patients should be monitored during and for an appropriate period of time after administration of BENLYSTA. The infusion must be discontinued immediately if the patient experiences a potentially life-threatening adverse reaction. Special Populations: Elderly: Limited data present, children: No data available, Renal and hepatic Impairment: No formal studies of BENLYSTA have been performed in patients with renal & hepatic impairment. Contraindications: BENLYSTA is contraindicated in patients who have demonstrated anaphylaxis to BENLYSTA. Warnings and Precautions: Caution should be exercised if BENLYSTA is co-administered with other B cell targeted therapy or cyclophosphamide because it has not been studied in combination with other B cell targeted therapy or intravenous cyclophosphamide. Administration of BENLYSTA may result in infusion and hypersensitivity reactions, which can be severe, and can be fatal. As with other immunomodulating agents, the mechanism of action of BENLYSTA may increase the potential risk for the development of infections. Progressive multifocal leukoencephalopathy (PML) resulting in neurological defi cits, including fatal cases, has been reported in SLE patients

receiving immunosuppressant pharmacotherapy, including BENLYSTA. Malignancy: As with other immunomodulating agents, the mechanism of action of BENLYSTA may increase the potential risk for the development of malignancies. Immunisation: Live vaccines should not be given for 30 days before, or concurrently with BENLYSTA as clinical safety has not been established. Fertility: There are no data on the effects of BENLYSTA on human fertility. Pregnancy: There are limited data on the use of BENLYSTA in pregnant women and it should be used during pregnancy only if the potential benefi t to the mother justifi es the potential risk to the foetus. Women of childbearing potential should take precautions to avoid pregnancy while being treated with BENLYSTA. Lactation: There are no data regarding the excretion of belimumab in human milk, or systemic absorption of belimumab after ingestion. However, belimumab was excreted into the milk of cynomolgous monkeys. There have been no studies to investigate the effect of BENLYSTA on driving performance or the ability to operate machinery. Adverse Reactions: Very common (≥ 1 in 10): Non-opportunistic infections. Common (≥ 1 in 100 and < 1 in 10): Hypersensitivity reaction, Pyrexia and Infusion-related reaction. Uncommon (≥ 1 in 1,000 and <1 in 100): Anaphylactic reaction, Angioedema, Rash and Urticaria. Overdose: There is no clinical experience with overdosage of BENLYSTA. Drug interactions: No drug interaction studies have been conducted with BENLYSTA. Concomitant use of mycophenolate mofetil, azathioprine, methotrexate and hydroxychloroquine did not substantially infl uence belimumab pharmacokinetics. Neither did a wide range of other co-medications (non-steroidal anti-infl ammatory medications, aspirin, and HMG-CoA reductase inhibitors), Steroids and ACE inhibitors resulted in a statistically signifi cant increase of systemic clearance in the population pharmacokinetic analysis. However, these effects were not clinically meaningful. Incompatibilities: BENLYSTA is not compatible with 5% dextrose. BENLYSTA prescribing Information Version number: GDS11IPI09, Date of issue: 09 December 2013.

For full prescribing information, please refer to the data sheet or contact GlaxoSmithKline: P.O. Box 50199, Dubai, United Arab Emirates.

Telephone: Bahrain +973 1 7377053, Kuwait +965 2 2053233, Oman +968 2 4571317, Qatar +974 44065455, UAE +971 4 4037100, KSA +966 12 653 6666.

To report Product Complaint/s or Adverse Event/s associated with the use of GSK product/s, please contact us via [email protected]

GCC/BEL/0013/17a Date of Preparation September 2017

Cutterguide: N/A Printing Process: OffsetGD: VV27293

Size: A4 (210 x 297) mm, Pages: 1 Colors: C M Y K (4 Color)Native File: Indesign CS5 Windows Generated in: Acrobat Distiller XI

● Could it be time to consider adding BENLYSTA instead of more of the same?

● Adding BENLYSTA provided signifi cant benefi ts vs. standard therapy alone in patients with persistent disease activity.1,2,*,†

Benlysta_Advert_GSKDC-PT-ARE-2017-1908_D3.indd 1 9/11/2017 3:30:34 PM



22

ACKNOWLEDGEMENTS

Platinum

Diamond

Gold

Contributors

We wish to thank the following companies who, through their generosityhave helped make this Congress possible

Associations

Official Congress Organizers

Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

LEBANON UAE

|DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475



23

COMPANIES PROFILE

Pfizer Lilly

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.At Pfizer, we’re committed to creating an environment where our colleagues can achieve success while contributing to the improved health of the world. We walk in as scientists, managers, manufacturers, senior executives and recent graduates. No matter where we come from or where we take our careers, we share a common purpose to make the world a healthier place.

One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. With a proven track record for providing medicines, vaccines and consumer products, the company has a long-standing innovation history of over 300 years and its presence in the Gulf Cooperation Council (GCC) has been expanding for the last 65 years – providing greater access and innovation to people in the region ever since. For further information please visit www.gsk.com

Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. www.novartis.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism

GlaxoSmithKline



24

COMPANIES PROFILE

Abbvie

ACR

ESR

Saudi Society for Rheumatology

Abbvie may have been founded in 2013, but our roots run deep. In 2013, we became a separate company from Abbott, though we share a common legacy and strong prospects for future success.Our name represents our connection to the past and the future. When we became our own company, AbbVie formed a new kind of enterprise - a biopharmaceutical company. We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech.Today, our ~29,000 employees around the world focus on delivering transformational medicines and therapies that offer significant patient benefits.

The American College of Rheumatology is an international medical society representing over 9,600 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care.

The Emirates Society for Rheumatology ESR was founded in 2008 and the current president is Dr. Waleed AlShehhi, who is a Consultant Rheumatologist at Dr. Sulaiman AlHabib Medical Centre and hospital, Dubai Health Care City. His term of presidency runs from January 2016 to January 2019. The society aims to increase awareness and standard of health professionals to have arthritis and musculoskeletal conditions diagnosed early, treated effectively and prevented where ever possible in the hope that early and correct diagnosis will lead to improve patient’s well being and a prosperous future. ESR is committed in supporting health care providers in their work by providing them with high-quality professional orientations and guidance. Collaboration with other medical and surgical specialties is at the heart of their core values.

VisionSSR aims to be a leading organization in the field of Rheumatology with significant positive impact on patient care in Saudi Arabia.

MissionTo Support our members to deliver the best care and advance the science of rheumatology which will impact on children and adult’s lives with rheumatic and musculoskeletal diseases in Saudi Arabia.

متغجطا

لروض ا

الةمسغئ السسعدغئ فطرا

SA

UD

I S O C I E T Y F O R R H E U MA T O

LO

GYS

. S . R



25

COMPANIES PROFILE

Pakistan Society for Rheumatology

Zaidi Chair of Research in Rheumatic Diseases

Pakistan Society for Rheumatology is a pioneering platform which was formed in 1995, with a view to enhance the knowledge about rheumatic diseases in Pakistan and to encourage further development of expertise in this field.It was in the early 1990’s that a small group of Rheumatologists who had trained in the UK and USA returned to Pakistan with the commitment to introduce advanced Rheumatology education and care. With the blessing of the old guard, the flame was passed on to the new generation and since then there has been no looking back.The first set of office bearers included Dr. Azra Ali (President), Dr. Khurram Manzoor Chowdhry (President-elect), Dr. Abid Farooqi (General Secretary), Dr Kamran Hameed (Joint Secretary) and Dr. Shahid Abbas (Finance Secretary). The first set of office bearers succeeded in getting the credentials of the Society accepted internationally within a few months by Asia Pacific league of associations for Rheumatology (APLAR).Within this short span of time a number of international publications of original scientific research have appeared in leading rheumatology journals and Pakistan’s name is beginning to be credible in the world of Rheumatology today.

VisionTo make Umm Al-Qura university the leader in carrying out, supervising and participating in the doing researches in the field of rheumatic diseases in Saudi Arabia

MissionProvide an appropriate scientific atmosphere to do scientific researches in the field of rheumatic diseases,and to give technical support to researchers and scientists. Also, participate in international scientific research in rheumatic diseases.

Infomed was established in 1993 and is one of the region’s leading event management companies. The key strengths of Infomed have remained constant, delivering events that are innovative, interesting, memorable and enabling every client to consistently achieve and surpass their event goals.Their reputation and longstanding loyalty of their clients are both clear testimonies to the quality of their work.Well known within the pharmaceutical and medical industries as a leading medicinal events management company, Infomed is also proud to be accredited by the International Association of Professional Congress Organizers (IAPCO).For more Information, Kindly visit: www.infomedweb.com

Official Congress Organizers: Infomed



26

Organized by: 4th Floor, Qubic CenterDaoud Ammoun StreetHorsh Tabet - Sin El FilP.O. Box: 90-361 BeirutTel: +961 1 510880/1/2/3 Mobile: +961 71 103123

LEBANON UAE

|DMCC Business CentreAlmas TowerJumeirah Lakes Dubai, United Arab EmiratesUnit No: 3820Mobile: +971 50 9110475

17 - american college of rheumatology · welcome address by acr president 3 welcome address by esr...

Documents